Post by bernstein on Jan 18, 2017 17:08:44 GMT
HOT FDA Play
NEOS (MC $91 M) $60 M Cash / 1 Drug approved /2 Drugs awaiting FDA approval (2Q & 4Q) targeting Billion Dollar Markets .
Very attractive and unknown low float FDA play with HUGE upside Potential i see the fair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $93 M
Cash: $60 M
Price $5.90
Shares Out: 16.06 M
Presentation
investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
NEOS (MC $91 M) $60 M Cash / 1 Drug approved /2 Drugs awaiting FDA approval (2Q & 4Q) targeting Billion Dollar Markets .
Very attractive and unknown low float FDA play with HUGE upside Potential i see the fair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $93 M
Cash: $60 M
Price $5.90
Shares Out: 16.06 M
Presentation
investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016